Next Article in Journal
Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [18F]fluorocholine PET/CT
Next Article in Special Issue
Diagnostics for Developing Countries
Previous Article in Journal
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
Previous Article in Special Issue
Technologies for Clinical Diagnosis Using Expired Human Breath Analysis
Article Menu

Export Article

Open AccessArticle
Diagnostics 2015, 5(2), 177-188;

A Novel Point-of-Care Biomarker Recognition Method: Validation by Detecting Marker for Diabetic Nephropathy

Department of Anesthesiology, Stony Brook Medical Center, Stony Brook, New York, NY 11794-8480, USA
Author to whom correspondence should be addressed.
Academic Editor: Andreas Kjaer
Received: 12 March 2015 / Revised: 13 April 2015 / Accepted: 14 April 2015 / Published: 23 April 2015
(This article belongs to the Special Issue In Vitro Diagnostics)
Full-Text   |   PDF [649 KB, uploaded 23 April 2015]   |  


Biological fluid collection to identify and analyze different disease markers is a routine and normal procedure in health care settings. Body fluids are as varied as urine, blood, mucus, cerebrospinal fluid (CSF), tears, semen, etc. The volumes of the collected fluids range from micro liters (e.g., tears, CSF) to tens and hundreds of milliliters (blood, urine, etc.). In some manifestations, a disease marker (particularly protein markers) can occur in trace amounts, yet the fluids collected are in large volumes. To identify these trace markers, cumbersome methods, expensive instruments, and trained personnel are required. We developed an easy method to rapidly capture, concentrate, and identify protein markers in large volumes of test fluids. This method involves the utilization of two antibodies recognizing two different epitopes of the protein biomarker. Antibody-1 helps to capture and concentrate the biomarker and Antibody-2 adsorbed or conjugated to nanogold beads will detect the biomarker. This method was validated in capturing and detecting lipocalin type prostaglandin-D2 synthase, a marker in urine that implicates diabetic nephropathy. A one-step collection, concentration, and detection device was designed based on this method. This device can replace many of the normal body fluid collection devices such as tubes and containers. A one-step fluid collection and biomarker capture and concentration device for rapid diagnosis of diseases has tremendous advantage in terms of cost and providing timely results. View Full-Text
Keywords: biomarker; point-of-care; antibody; diabetic nephropathy biomarker; point-of-care; antibody; diabetic nephropathy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Pentyala, S.; Muller, J.; Tumillo, T.; Roy, A.; Mysore, P.; Pentyala, S. A Novel Point-of-Care Biomarker Recognition Method: Validation by Detecting Marker for Diabetic Nephropathy. Diagnostics 2015, 5, 177-188.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top